SHC — Sotera Health Company

Sotera Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year 2025 Performance:

  • Total revenue: $1.164 billion, up 5.7% (5.2% constant currency).
  • Adjusted EBITDA: $593.8 million, up 8.2% (7.8% constant currency), with margins at 51%.
  • Adjusted free cash flow: Over $200 million.
  • Net income: $78 million ($0.27 per diluted share).
  • Adjusted EPS: $0.86, an increase of $0.16 from 2024.

• Q4 2025 Performance:

  • Total revenue: $303 million, up 4.6% (2.5% constant currency).
  • Adjusted EBITDA: $157 million, up 2.7% (0.5% constant currency), with margins at 51.8%.
  • Net income: $35 million ($0.12 per diluted share).
  • Adjusted EPS: $0.26, up $0.05 from Q4 2024.

2. Strategic Updates and Business Highlights

• Growth Initiatives:

  • 20 consecutive years of revenue growth.
  • Customer satisfaction exceeded 80%.
  • Notable revenue growth from XBU customers (up 9% year-over-year) and Sterigenics (up 8% constant currency).
  • Significant progress on facility enhancements, including an EO facility and a new X-ray facility set to open in 2026.
  • Successful debt management, reducing borrowing costs and paying down $86 million in debt.

• Corporate Governance:

  • Appointment of Richard Kyle to the Board and promotion of Erika Ostrowski to Senior Vice President and General Counsel.

3. Forward Guidance and Outlook

• 2026 Expectations:
  • Revenue projected between $1.233 billion and $1.251 billion (5% to 6.5% constant currency growth).
  • Adjusted EBITDA expected between $632 million and $641 million (5.5% to 7% constant currency growth).
  • Anticipated interest expense: $135 million to $145 million.
  • Adjusted EPS forecasted between $0.93 and $1.01.
  • Capital expenditures expected to range from $175 million to $225 million.

4. Bad News, Challenges, or Points of Concern

• Segment-Specific Challenges:

  • Nordion's revenue decreased by 12.3% due to Cobalt-60 harvest timing, impacting volume and mix.
  • Nelson Labs faced headwinds from declining Expert Advisory Services revenue, with expectations of low single-digit growth in 2026.
  • The commercial segment of Sterigenics is experiencing challenges, with some customers downsizing or redesigning products, leading to volume shrinkage.

• Regulatory Environment:

  • The NESHAP compliance deadline extension has slowed outsourcing decisions from clients, impacting growth momentum.

5. Notable Q&A Insights

• Volume and Pricing Dynamics:

  • Management indicated that volume and mix will be crucial for reaching the higher end of revenue guidance.
  • Sterigenics is expected to see mid-single-digit growth in Q1 2026, with a soft start attributed to shutdowns and weather impacts.

• Competitive Positioning:

  • Management remains confident in Sterigenics' competitive position despite the NESHAP extension, emphasizing strong customer satisfaction and a robust global platform.

• Future Capacity Expansion:

  • Discussions for additional capacity expansions will occur during the annual strategic planning process, with a focus on maintaining long-term growth targets.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A, providing a comprehensive overview of Sotera Health's performance and outlook for 2026.